Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goldhirsch

Showing results (401-410 of 753) with videos related to

Pageof 76
Sort By:
Oncology|August 21, 2008
Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choiceChiara Catania, Tommaso De Pas, Aron Goldhirsch, et al.
Clinical Breast Cancer|March 1, 2018
Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast CancerAntonella Palazzo, Silvia Dellapasqua, Elisabetta Munzone, et al.
Breast (Edinburgh, Scotland)|July 20, 2010
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancerRosalba Torrisi, Emilia Montagna, Eloise Scarano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2005
Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543-1550): ... and in humans?T De Pas, M Colleoni, L Orlando, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study GroupC Hürny, J Bernhard, R D Gelber, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VIIPer Karlsson, Bernard F Cole, Karen N Price, et al.
Breast Cancer Research and Treatment|September 13, 2005
Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancerChiara Catania, Florence Didier, Maria Elena Leon, et al.
Anti-Cancer Drugs|August 31, 2006
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancerLaura Orlando, Anna Cardillo, Andrea Rocca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2012
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesG Curigliano, D Cardinale, T Suter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 1997
Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burdenF Nolè, F de Braud, M Aapro, et al.
Pageof 76

Showing results (401-410 of 753) with videos related to

Sort By:
Pageof 76
Oncology|August 21, 2008
Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choiceChiara Catania, Tommaso De Pas, Aron Goldhirsch, et al.
Clinical Breast Cancer|March 1, 2018
Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast CancerAntonella Palazzo, Silvia Dellapasqua, Elisabetta Munzone, et al.
Breast (Edinburgh, Scotland)|July 20, 2010
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancerRosalba Torrisi, Emilia Montagna, Eloise Scarano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2005
Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543-1550): ... and in humans?T De Pas, M Colleoni, L Orlando, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study GroupC Hürny, J Bernhard, R D Gelber, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VIIPer Karlsson, Bernard F Cole, Karen N Price, et al.
Breast Cancer Research and Treatment|September 13, 2005
Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancerChiara Catania, Florence Didier, Maria Elena Leon, et al.
Anti-Cancer Drugs|August 31, 2006
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancerLaura Orlando, Anna Cardillo, Andrea Rocca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2012
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesG Curigliano, D Cardinale, T Suter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 1997
Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burdenF Nolè, F de Braud, M Aapro, et al.
Pageof 76